GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis-Reference-Cited by-同舟云学术

GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis

Published:2019-06-25 Issue:6 Volume:14 Page:e0217701
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Grenet Guillaume^ORCID,Ribault Shams,Nguyen Giao Bao,Glais Faustine,Metge Augustin^ORCID,Linet Thomas,Kassai-Koupai Behrouz,Cornu Catherine,Bejan-Angoulvant Théodora,Erpeldinger Sylvie,Boussageon Rémy,Gouraud Aurore,Bonnet Fabrice,Cucherat Michel,Moulin Philippe,Gueyffier François

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference63 articles.

1. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes;SC Palmer;A Meta-analysis. JAMA,2016

2. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes;B Zinman;N Engl J Med,2015

3. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes;B Neal;N Engl J Med,2017

4. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes;SP Marso;N Engl J Med,2016

5. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes;SP Marso;N Engl J Med,2016

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management;Diabetologia;2024-08-19

2. Fondamentaux de l’évaluation des thérapeutiques, médicamenteuses et non médicamenteuses – un cadre pour l’évaluation des processus d’autoguérison;Hegel;2024-01-18

3. Cardiometabolic risk profile of young and old adults with diabetes: Pooled, cross-sectional analysis of 42 national health surveys;Primary Care Diabetes;2023-12

4. L’aspirine a-t-elle une place dans la prévention cardiovasculaire primaire par la polypill ? Étude de simulation sur une population virtuelle réaliste;Therapies;2023-11

5. Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents;The Lancet Diabetes & Endocrinology;2023-09